{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:35:06Z","timestamp":1763764506374},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,5,2]],"date-time":"2006-05-02T00:00:00Z","timestamp":1146528000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Prostate cancer that has recurred after local therapy or disseminated distantly is usually treated with androgen deprivation therapy; however, most men will eventually experience disease progression within 12 to 20 months. New data emerging from randomized controlled trials (RCTs) of chemotherapy provided the impetus for a systematic review addressing the following question: which non-hormonal systemic therapies are most beneficial for the treatment of men with hormone-refractory prostate cancer (HRPC) and clinical evidence of metastases?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review was performed to identify RCTs or meta-analyses examining first-line non-hormonal systemic (cytotoxic and non-cytotoxic) therapy in patients with HRPC and metastases that reported at least one of the following endpoints: overall survival, disease control, palliative response, quality of life, and toxicity. Excluded were RCTs of second-line hormonal therapies, bisphosphonates or radiopharmaceuticals, or randomized fewer than 50 patients per trial arm. MEDLINE, EMBASE, the Cochrane Library, and the conference proceedings of the American Society of Clinical Oncology were searched for relevant trials. Citations were screened for eligibility by four reviewers and discrepancies were handled by consensus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 80 RCTs identified, 27 met the eligibility criteria. Two recent, large trials reported improved overall survival with docetaxel-based chemotherapy compared to mitoxantrone-prednisone. Improved progression-free survival and rates of palliative and objective response were also observed. Compared with mitoxantrone, docetaxel treatment was associated with more frequent mild toxicities, similar rates of serious toxicities, and better quality of life. More frequent serious toxicities were observed when docetaxel was combined with estramustine. Three trials reported improved time-to-disease progression, palliative response, and\/or quality of life with mitoxatrone plus corticosteroid compared with corticosteroid alone. Single trials reported improved disease control with estramustine-vinblastine, vinorelbine-hydrocortisone, and suramin-hydrocortisone compared to controls. Trials of non-cytotoxic agents have reported equivocal results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Docetaxel-based chemotherapy modestly improves survival and provides palliation for men with HRPC and metastases. Other than androgen deprivation therapy, this is the only other therapy to have demonstrated improved overall survival in prostate cancer in RCTs. Further investigations to identify more effective therapies for HRPC including the use of systemic therapies earlier in the natural history of prostate cancer are warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-6-112","type":"journal-article","created":{"date-parts":[[2006,5,2]],"date-time":"2006-05-02T20:22:59Z","timestamp":1146601379000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group"],"prefix":"10.1186","volume":"6","author":[{"given":"Eric","family":"Winquist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricia","family":"Waldron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Scott","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Hotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himu","family":"Lukka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,2]]},"reference":[{"key":"464_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cncr.20288","volume":"101","author":"A Jemal","year":"2004","unstructured":"Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM: Annual report to the Nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004, 101: 3-27. 10.1002\/cncr.20288.","journal-title":"Cancer"},{"key":"464_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1464-410X.2005.05798.x","volume":"96","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, Gulley JL: A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005, 96: 985-989. 10.1111\/j.1464-410X.2005.05798.x.","journal-title":"BJU Int"},{"key":"464_CR3","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1002\/1097-0142(19931215)72:12+<3793::AID-CNCR2820721706>3.0.CO;2-U","volume":"72","author":"DW Newling","year":"1993","unstructured":"Newling DW, Dennis L, Vermylen K: Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer. 1993, 72: 3793-3798. 10.1002\/1097-0142(19931215)72:12+<3793::AID-CNCR2820721706>3.0.CO;2-U.","journal-title":"Cancer"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE: Skeletal complications of malignancy. Cancer. 1997, 80: 1588-1594. 10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G.","journal-title":"Cancer"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/S0022-5347(01)62501-1","volume":"160","author":"WK Oh","year":"1998","unstructured":"Oh WK, Kantoff PW: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998, 160: 1220-1229. 10.1097\/00005392-199810000-00003.","journal-title":"J Urol"},{"key":"464_CR6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","volume":"13","author":"GP Browman","year":"1995","unstructured":"Browman GP, Levine MN, Mohide EA, Hayward RSA, Pritchard KI, Gafni A, Laupacis A: The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995, 13: 502-512.","journal-title":"J Clin Oncol"},{"key":"464_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/9780470693926.ch11","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M, Smith GD: Investigating and dealing with publication and other biases. Systematic Reviews in Health Care: Meta-analysis in Context. Edited by: Egger M, Smith GD, Altman D. 2001, London: BMJ Publishing Group, 189-208."},{"key":"464_CR8","first-page":"24","volume":"68","author":"WW Scott","year":"1977","unstructured":"Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP: The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. Trans Am Assoc Genitourin Surg. 1977, 68: 24-28.","journal-title":"Trans Am Assoc Genitourin Surg"},{"key":"464_CR9","first-page":"115","volume":"60","author":"RT Eagan","year":"1976","unstructured":"Eagan RT, Hahn RG, Myers RP: Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treatment Reports. 1976, 60: 115-117.","journal-title":"Cancer Treatment Reports"},{"key":"464_CR10","first-page":"311","volume":"61","author":"LK Kvols","year":"1977","unstructured":"Kvols LK, Eagan RT, Myers RP: Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report. Cancer Treatment Reports. 1977, 61: 311-312.","journal-title":"Cancer Treatment Reports"},{"key":"464_CR11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-5347(17)57975-6","volume":"118","author":"GP Murphy","year":"1977","unstructured":"Murphy GP, Gibbons RP, Johnson DE, Loening SA, Prout GR, Schmidt JD, Bross DS, Chu TM, Gaeta JF, Saroff J, Scott WW: A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive irradiation. J Urol. 1977, 118: 288-291.","journal-title":"J Urol"},{"key":"464_CR12","first-page":"1589","volume":"61","author":"F Tejada","year":"1977","unstructured":"Tejada F, Eisenberger MA, Broder LA, Cohen MH, Simon R: 5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treatment Reports. 1977, 61: 1589-1590.","journal-title":"Cancer Treatment Reports"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1002\/1097-0142(197812)42:6<2546::AID-CNCR2820420607>3.0.CO;2-C","volume":"42","author":"RT Chlebowski","year":"1978","unstructured":"Chlebowski RT, Hestorff R, Sardoff L, Weiner J, Bateman JR: Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. Cancer. 1978, 42: 2546-2552. 10.1002\/1097-0142(197812)42:6<2546::AID-CNCR2820420607>3.0.CO;2-C.","journal-title":"Cancer"},{"key":"464_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-5347(17)56714-2","volume":"121","author":"JD Schmidt","year":"1979","unstructured":"Schmidt JD, Scott WW, Gibbons RP, Johnson DE, Prout GR, Loening SA, Soloway MS, Chu TM, Gaeta JF, Slack NH, Saroff J, Murphy GP: Comparison of procarbazine, imidazole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J Urol. 1979, 121: 185-189.","journal-title":"J Urol"},{"key":"464_CR15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0022-5347(17)55216-7","volume":"125","author":"SA Loening","year":"1981","unstructured":"Loening SA, Scott WW, deKernion J, Gibbons RP, Johnson DE, Pontes JE, Prout GR, Schmidt JD, Soloway MS, Chu TM, Gaeta JF, Slack NH, Murphy GP: A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J Urol. 1981, 125: 812-816.","journal-title":"J Urol"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/1097-0142(19810415)47:8<1949::AID-CNCR2820470806>3.0.CO;2-3","volume":"47","author":"HB Muss","year":"1981","unstructured":"Muss HB, Howard V, Richards F, White DR, Jackson DV, Cooper MR, Stuart JJ, Resnick MI, Brodkin R, Spurr CL: Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer. 1981, 47: 1949-1953. 10.1002\/1097-0142(19810415)47:8<1949::AID-CNCR2820470806>3.0.CO;2-3.","journal-title":"Cancer"},{"key":"464_CR17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0022-5347(17)54961-7","volume":"125","author":"RV Smalley","year":"1981","unstructured":"Smalley RV, Bartolucci AA, Hemstreet G, Hester M: A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol. 1981, 125: 191-195.","journal-title":"J Urol"},{"key":"464_CR18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0022-5347(17)55156-3","volume":"125","author":"MS Soloway","year":"1981","unstructured":"Soloway MS, Dekernion JB, Gibbons RP, Johnson DE, Loening SA, Pontes JE, Prout GR, Schmidt JD, Scott WW, Chu TM, Gaeta JF, Slack NH, Murphy GP: Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol. 1981, 125: 664-667.","journal-title":"J Urol"},{"key":"464_CR19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0022-5347(17)53866-5","volume":"127","author":"HW Herr","year":"1982","unstructured":"Herr HW: Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer. J Urol. 1982, 127: 462-465.","journal-title":"J Urol"},{"key":"464_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pros.2990040102","volume":"4","author":"WD DeWys","year":"1983","unstructured":"DeWys WD, Begg CB, Brodovsky H, Creech R, Khandekar J: A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. Prostate. 1983, 4: 1-11.","journal-title":"Prostate"},{"key":"464_CR21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(17)51917-5","volume":"129","author":"MS Soloway","year":"1983","unstructured":"Soloway MS, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Murphy GP: A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who have had extensive irradiation to the pelvis or lumbosacral area. J Urol. 1983, 129: 56-61.","journal-title":"J Urol"},{"key":"464_CR22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.1985.3.3.385","volume":"3","author":"BS Kasimis","year":"1985","unstructured":"Kasimis BS, Miller JB, Kaneshiro CA, Forbes KA, Moran EM, Metter GE: Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol. 1985, 3: 385-392.","journal-title":"J Clin Oncol"},{"key":"464_CR23","first-page":"105","volume":"69","author":"JP Page","year":"1985","unstructured":"Page JP, Levi JA, Woods RL, Tattersall MN, Fox RM, Coates AS: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma. Cancer Treatment Reports. 1985, 69: 105-107.","journal-title":"Cancer Treatment Reports"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/1097-0142(19851201)56:11<2580::AID-CNCR2820561108>3.0.CO;2-W","volume":"56","author":"FM Torti","year":"1985","unstructured":"Torti FM, Shortliffe LD, Carter SK, Hannigan JF, Aston D, Lum BL, Williams RD, Spaulding JT, Freiha FS: A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer. 1985, 56: 2580-2586. 10.1002\/1097-0142(19851201)56:11<2580::AID-CNCR2820561108>3.0.CO;2-W.","journal-title":"Cancer"},{"key":"464_CR25","first-page":"177","volume":"303","author":"RC Benson Jr","year":"1989","unstructured":"Benson RC, Cummings K: Estramustine phosphate vs. diethylstilbestrol in the treatment of stage D prostate cancer. Prog Clin Biol Res. 1989, 303: 177-186.","journal-title":"Prog Clin Biol Res"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/0090-4295(86)90074-9","volume":"28","author":"SD Graham","year":"1986","unstructured":"Graham SD, Walker A, Cox EB, Laszlo J, Berry WR, Paulson DF: Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. Urology. 1986, 28: 404-408. 10.1016\/0090-4295(86)90074-9.","journal-title":"Urology"},{"key":"464_CR27","first-page":"343","volume":"18","author":"H Akaza","year":"1988","unstructured":"Akaza H, Isurugi K, Oishi Y, Kitajima K, Sawamura Y, Baba S, Yoshida K, Otani M, Harada M, Gunji A: A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents. Jpn J Clin Oncol. 1988, 18: 343-355.","journal-title":"Jpn J Clin Oncol"},{"key":"464_CR28","first-page":"2507","volume":"23","author":"S Kitahara","year":"1988","unstructured":"Kitahara S, Fukui I, Higashi Y, Kihara K, Takeuchi S, Oshima H, Negishi T, Hosoda K, Kawai T, Ikegami S: [A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report)] [Japanese]. Nippon Gan Chiryo Gakkai Shi. 1988, 23: 2507-2513.","journal-title":"Nippon Gan Chiryo Gakkai Shi"},{"key":"464_CR29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.1988.6.9.1456","volume":"6","author":"A Manni","year":"1988","unstructured":"Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon R: Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol. 1988, 6: 1456-1466.","journal-title":"J Clin Oncol"},{"key":"464_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0090-4295(88)90419-0","volume":"32","author":"DG McLeod","year":"1988","unstructured":"McLeod DG, Murphy GP, Priore R: Comparison of megace, stilphostrol, megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. Urology. 1988, 32: 431-436. 10.1016\/0090-4295(88)90419-0.","journal-title":"Urology"},{"issue":"Suppl 3","key":"464_CR31","first-page":"26","volume":"12","author":"I Papadopoulos","year":"1989","unstructured":"Papadopoulos I, Wand H: [Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study] [German]. Onkologie. 1989, 12 (Suppl 3): 26-31.","journal-title":"Onkologie"},{"key":"464_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000226734","volume":"46","author":"P Ruff","year":"1989","unstructured":"Ruff P, Derman DP, Weaving A, Bezwoda WR: Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer. Oncology. 1989, 46: 288-292.","journal-title":"Oncology"},{"key":"464_CR33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000463890","volume":"18","author":"A Shafik","year":"1990","unstructured":"Shafik A: Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route \u2013 preliminary study. Eur Urol. 1990, 18: 132-136.","journal-title":"Eur Urol"},{"key":"464_CR34","first-page":"243","volume":"24","author":"KJ Tveter","year":"1990","unstructured":"Tveter KJ, Hagen S, Holme I, Klepp O, Kloster SE, Muri O, Poulsen C, Sander S, Sivertsen S, Urnes T: A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Scand J Urol Nephrol. 1990, 24: 243-247.","journal-title":"Scand J Urol Nephrol"},{"key":"464_CR35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000473570","volume":"19","author":"I Elomaa","year":"1991","unstructured":"Elomaa I, Kellokumpu-Lehtinen P, Rannikko S, Alfthan O: Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol. 1991, 19: 12-15.","journal-title":"Eur Urol"},{"key":"464_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0090-4295(92)90023-P","volume":"39","author":"C Rangel","year":"1992","unstructured":"Rangel C, Matzkin H, Soloway MS: Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer. Urology. 1992, 39: 577-582. 10.1016\/0090-4295(92)90023-P.","journal-title":"Urology"},{"key":"464_CR37","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/bjc.1993.265","volume":"67","author":"G Francini","year":"1993","unstructured":"Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A, Mondillo S: Weekly chemotherapy in advanced prostatic cancer. Br J Cancer. 1993, 67: 1430-1436.","journal-title":"Br J Cancer"},{"key":"464_CR38","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0022-5347(01)67467-6","volume":"153","author":"DD Daliani","year":"1995","unstructured":"Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ: The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol. 1995, 153: 1587-1591. 10.1097\/00005392-199505000-00064.","journal-title":"J Urol"},{"key":"464_CR39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000480825","volume":"32","author":"J Breul","year":"1997","unstructured":"Breul J, Jakse G, Forster G, Lampel A, Rohani A, Hartung R: 5-fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial. Eur Urol. 1997, 32: 280-283.","journal-title":"Eur Urol"},{"key":"464_CR40","first-page":"316a","volume":"17","author":"D Brune","year":"1998","unstructured":"Brune D: Phase III trial of pirarubicin versus palliative treatment in hormone-refractory prostatic cancer [abstract]. Proc Am Soc Clin Oncol. 1998, 17: 316a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000020291","volume":"38","author":"G Van Andel","year":"2000","unstructured":"Van Andel G, Kurth KH, Rietbroek RL, Van de Velde-Muusers JA: Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate \u2013 Is it feasible?. Eur Urol. 2000, 38: 259-264. 10.1159\/000020291.","journal-title":"Eur Urol"},{"key":"464_CR42","first-page":"183a","volume":"21","author":"W Dahut","year":"2002","unstructured":"Dahut W, Arlen P, Gulley J, Parker C, Fedenko K, Noone M, Hamilton M: A randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 183a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR43","first-page":"1888","volume":"7","author":"WD Figg","year":"2001","unstructured":"Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001, 7: 1888-1893.","journal-title":"Clin Cancer Res"},{"key":"464_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1078-1439(00)00123-X","volume":"6","author":"R Millikan","year":"2001","unstructured":"Millikan R, Baez L, Banerjee T, Wade J, Edwards K, Winn R, Smith TL, Logothetis C: Randomized phase 2 trial of ketoconazole and ketoconazole\/doxorubicin in androgen independent prostate cancer. Urol Oncol. 2001, 6: 111-115. 10.1016\/S1078-1439(00)00123-X.","journal-title":"Urol Oncol"},{"key":"464_CR45","first-page":"177","volume":"21","author":"P Hervonen","year":"2002","unstructured":"Hervonen P, Lehtinen T, Tammela TL, Kellokumpu-Lehtinen P: A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC). J Exp Clin Cancer Res. 2002, 21: 177-180.","journal-title":"J Exp Clin Cancer Res"},{"key":"464_CR46","first-page":"407","volume":"22","author":"B Tombal","year":"2003","unstructured":"Tombal B, Tourani J-M, Fizazi K, Culine S, Lotz J-P, Ould Kaci M, Coppola F: Randomized phase II trial of irofulven (IROF) with or without prednisone in hormone-refractory prostate cancer (HRPC) patients (pts) [abstract]. Proc Am Soc Clin Oncol. 2003, 22: 407-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR47","first-page":"2530","volume":"8","author":"AW Tolcher","year":"2002","unstructured":"Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E: A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2002, 8: 2530-2535.","journal-title":"Clin Cancer Res"},{"key":"464_CR48","first-page":"177a","volume":"21","author":"S Oudard","year":"2002","unstructured":"Oudard S, Beuzeboc P, Dourthe LM, Voog E, Hardy-Bessard AC, Coscas I, Chauvet B: Preliminary results of a phase II randomized trial of docetaxel (D), estramustine (E), and prednisone (P) \u2013 two schedules \u2013 versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 177a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR49","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdg342","volume":"14","author":"JP Droz","year":"2003","unstructured":"Droz JP, Muracciole X, Mottet N, Ould KM, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G: Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003, 14: 1291-1298. 10.1093\/annonc\/mdg342.","journal-title":"Ann Oncol"},{"key":"464_CR50","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2003.04.057","volume":"21","author":"R Millikan","year":"2003","unstructured":"Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J, Logothetis CJ: Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003, 21: 878-883. 10.1200\/JCO.2003.04.057.","journal-title":"J Clin Oncol"},{"key":"464_CR51","first-page":"429","volume":"22","author":"M Salimichokami","year":"2003","unstructured":"Salimichokami M: Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone refractory prostate cancer (HRPC), a randomized study of weekly docetaxel alone or in combination with thalidomide [abstract]. Proc Am Soc Clin Oncol. 2003, 22: 429-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.2004.11.973","volume":"22","author":"CN Sternberg","year":"2003","unstructured":"Sternberg CN, Hetherington JW, Paluchowska B, Slee PH, Collette L, Debois M, Zurlo A: Randomized phase III trial of a new oral platinum, satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol. 2003, 22: 395-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR53","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00345-003-0342-3","volume":"21","author":"G Van Andel","year":"2003","unstructured":"Van Andel G, Fernandez de Moral P, Caris CT, Carpentier P, Wils J, de Bruin MJ, Witjes JA, Debruyne FM, Witjes WP: A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol. 2003, 21: 177-182. 10.1007\/s00345-003-0342-3.","journal-title":"World J Urol"},{"key":"464_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/sj.bjc.6601468","volume":"90","author":"W Albrecht","year":"2004","unstructured":"Albrecht W, Van Poppel H, Horenblas S, Mickisch G, Horwich A, Serretta V, Casetta G, Marechal JM, Jones WG, Kalman S, Sylvester R: Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer. 2004, 90: 100-105. 10.1038\/sj.bjc.6601468.","journal-title":"Br J Cancer"},{"key":"464_CR55","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.urology.2003.08.041","volume":"63","author":"MA Dimopoulos","year":"2004","unstructured":"Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M: Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology. 2004, 63: 120-125. 10.1016\/j.urology.2003.08.041.","journal-title":"Urology"},{"key":"464_CR56","first-page":"411","volume":"23","author":"R Birch","year":"2004","unstructured":"Birch R, Kalman L, Holt L, Graham B, Wheeler B, Schwartzberg L: Randomized phase IIb trial comparing two schedules of docetaxel (D) plus estramustine (E) for metastatic hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 411-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR57","first-page":"406","volume":"23","author":"J-C Eymard","year":"2004","unstructured":"Eymard J-C, Joly F, Priou F, Zannetti A, Ravaud A, Kerbrat P, Mousseau M: Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 406-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR58","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.clon.2004.04.003","volume":"23","author":"WK Kelly","year":"2004","unstructured":"Kelly WK, Galsky MD, Small EJ, Oh W, Chen I, Smith D, Martone L: Multi-institutional trial of the epothiline B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): updated results [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 383-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR59","first-page":"417","volume":"23","author":"PN Lara","year":"2004","unstructured":"Lara PN, Longmate J, Stadler W, Quinn DI, Twardowski P, Martel CI, Vogelzang NJ: Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): a randomized trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291 [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 417-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR60","first-page":"395","volume":"23","author":"R Millikan","year":"2004","unstructured":"Millikan R, Thall P, Pagliaro L, Williams D, Brown M, Logothetis C: Randomized, adaptive, phase II selection trial of four chemotherapy regimens in androgen independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 395-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR61","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","volume":"17","author":"G Hudes","year":"1999","unstructured":"Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999, 17: 3160-3166.","journal-title":"J Clin Oncol"},{"key":"464_CR62","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdh429","volume":"15","author":"RP Abratt","year":"2004","unstructured":"Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, Beuzeboc P: Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004, 15: 1613-1621. 10.1093\/annonc\/mdh429.","journal-title":"Ann Oncol"},{"key":"464_CR63","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Maha PH, Hussain HA, Lara PN, Jones JA, Taplin ME: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351: 1513-1520. 10.1056\/NEJMoa041318.","journal-title":"N Engl J Med"},{"key":"464_CR64","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi K, Oudard S: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351: 1502-1512. 10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"key":"464_CR65","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0022-5347(01)65086-9","volume":"157","author":"P Iversen","year":"1997","unstructured":"Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S, Rosenkilde P: Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol. 1997, 157: 929-934. 10.1016\/S0022-5347(01)65086-9.","journal-title":"J Urol"},{"key":"464_CR66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1464-410X.1991.tb15259.x","volume":"68","author":"JE Johansson","year":"1991","unstructured":"Johansson JE, Andersson SO, Holmberg L: High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. Br J Urol. 1991, 68: 67-73.","journal-title":"Br J Urol"},{"key":"464_CR67","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0090-4295(88)90088-X","volume":"31","author":"JN de Kernion","year":"1988","unstructured":"de Kernion JN, Murphy GP, Priore R: Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer. Urology. 1988, 31: 312-317. 10.1016\/0090-4295(88)90088-X.","journal-title":"Urology"},{"key":"464_CR68","first-page":"69","volume":"70","author":"GP Murphy","year":"1979","unstructured":"Murphy GP, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Soloway MS, Loening SA, Chu TM, Gaeta JF, Saroff J, Wajsman Z, Slack N, Scott WW: The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Trans Am Assoc Genitourin Surg. 1979, 70: 69-71.","journal-title":"Trans Am Assoc Genitourin Surg"},{"key":"464_CR69","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0022-5347(05)64163-8","volume":"168","author":"W Berry","year":"2002","unstructured":"Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002, 168: 2439-2443. 10.1016\/S0022-5347(05)64163-8.","journal-title":"J Urol"},{"key":"464_CR70","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","volume":"17","author":"PW Kantoff","year":"1999","unstructured":"Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999, 17: 2506-2513.","journal-title":"J Clin Oncol"},{"key":"464_CR71","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996, 14: 1756-1764.","journal-title":"J Clin Oncol"},{"key":"464_CR72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000475185","volume":"27","author":"C Anderstr\u00f6m","year":"1995","unstructured":"Anderstr\u00f6m C, Eddeland A, Folmerz P, Hansson R, Milles S, Zachrisson B: Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study. Eur Urol. 1995, 27: 301-305.","journal-title":"Eur Urol"},{"key":"464_CR73","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/1097-0142(19920315)69:6<1440::AID-CNCR2820690622>3.0.CO;2-9","volume":"69","author":"JA Laurie","year":"1992","unstructured":"Laurie JA, Hahn RG, Therneau TM, Patel SR, Mailliard JA, Windschitl HE, Twito DI, Morton RF, Krook JE: Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer. 1992, 69: 1440-1444. 10.1002\/1097-0142(19920315)69:6<1440::AID-CNCR2820690622>3.0.CO;2-9.","journal-title":"Cancer"},{"key":"464_CR74","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1002\/1097-0142(19921115)70:10<2488::AID-CNCR2820701016>3.0.CO;2-9","volume":"70","author":"S Saxman","year":"1992","unstructured":"Saxman S, Ansari R, Drasga R, Miller M, Wheeler B, McClean J, Einhorn L: Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group Study. Cancer. 1992, 70: 2488-2492. 10.1002\/1097-0142(19921115)70:10<2488::AID-CNCR2820701016>3.0.CO;2-9.","journal-title":"Cancer"},{"key":"464_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0090-4295(88)90450-5","volume":"32","author":"GP Murphy","year":"1988","unstructured":"Murphy GP, Priore RL, Scardino PT: Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. Urology. 1988, 32: 33-40. 10.1016\/0090-4295(88)90450-5.","journal-title":"Urology"},{"key":"464_CR76","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1097-0142(19840201)53:3<406::AID-CNCR2820530307>3.0.CO;2-3","volume":"53","author":"RL Stephens","year":"1984","unstructured":"Stephens RL, Vaughn C, Lane M, Costanzi J, O'Bryan R, Balcerzak SP, Levin H, Frank J, Coltman CA: Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer. 1984, 53: 406-410. 10.1002\/1097-0142(19840201)53:3<406::AID-CNCR2820530307>3.0.CO;2-3.","journal-title":"Cancer"},{"key":"464_CR77","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0022-5347(17)35911-6","volume":"150","author":"DW Newling","year":"1993","unstructured":"Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R: Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study (30865). J Urol. 1993, 150: 1840-1844.","journal-title":"J Urol"},{"key":"464_CR78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0022-5347(17)52509-4","volume":"129","author":"SA Loening","year":"1983","unstructured":"Loening SA, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS, Murphy GP: Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol. 1983, 129: 1001-1006.","journal-title":"J Urol"},{"key":"464_CR79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","volume":"21","author":"MA Carducci","year":"2003","unstructured":"Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003, 21: 679-689. 10.1200\/JCO.2003.04.176.","journal-title":"J Clin Oncol"},{"key":"464_CR80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1385\/MO:20:2:137","volume":"20","author":"AN Leaf","year":"2003","unstructured":"Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE: Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol. 2003, 20: 137-146. 10.1385\/MO:20:2:137.","journal-title":"Med Oncol"},{"key":"464_CR81","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1200\/JCO.2002.10.022","volume":"20","author":"EJ Small","year":"0159","unstructured":"Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ: Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup Cancer and Leukemia Group B 9480. J Clin Oncol. 0159, 20: 3369-3375. 10.1200\/JCO.2002.10.022.","journal-title":"J Clin Oncol"},{"key":"464_CR82","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1200\/JCO.2000.18.7.1440","volume":"18","author":"EJ Small","year":"2000","unstructured":"Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000, 18: 1440-1450.","journal-title":"J Clin Oncol"},{"key":"464_CR83","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0090-4295(98)00129-0","volume":"52","author":"FJ Debruyne","year":"1998","unstructured":"Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P: Liarozole \u2013 a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 1998, 52: 72-81. 10.1016\/S0090-4295(98)00129-0.","journal-title":"Urology"},{"key":"464_CR84","first-page":"175a","volume":"20","author":"W Berry","year":"2001","unstructured":"Berry W, Gregurich M, Dakhil S, Hathorn J, Asmar L: Phase II randomized trial of weekly paclitaxel (Taxol\u00ae) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate (HRMCP) [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 175a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR85","first-page":"383","volume":"23","author":"M Carducci","year":"2004","unstructured":"Carducci M, Nelson JB, Saad F, Schulman C, Dearnaley DP, Sleep DJ, Hulting SM: Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 383-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR86","first-page":"382","volume":"22","author":"E Small","year":"2003","unstructured":"Small E, Rini B, Higano CS, Redfern C, Neumunaitis J, Valone F, Kylstra J: A randomized, placebo-controlled phase III trial of APC8015 in patients with androgen-independent prostate cancer (AIPCa) [abstract]. Proc Am Soc Clin Oncol. 2003, 22: 382-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR87","first-page":"174a","volume":"20","author":"FR Ahmann","year":"2001","unstructured":"Ahmann FR, Saad F, Mercier R, Huddart RA, Roberts JT, Collier M, Bettencourt L: Interim results of a phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic hormone refractory prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 174a-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"464_CR88","doi-asserted-by":"publisher","first-page":"5.1","DOI":"10.1007\/s001200050148","volume":"37","author":"L Weissbach","year":"1998","unstructured":"Weissbach L, Vogler H, Hofmann E, Knorr B: Palliative monochemotherapie des hormonrefrakt symptomat PCA's \u2013 ergebnisse einer prospektiven, randomisierten multizenterstudie. Urologe A. 1998, 37: 5.1-","journal-title":"Urologe A"},{"key":"464_CR89","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993, 11: 1566-1572.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-6-112\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-6-112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:37:04Z","timestamp":1630449424000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-6-112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,2]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-6-112","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,2]]},"assertion":[{"value":"3 November 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"112"}}